Merck’s Keytruda combo gets FDA nod for expanded use in cervical cancer

The Keytruda combination was approved for patients with cervical cancer who had not previously received surgery, radiation, or systemic therapy, FDA said. Keytruda is already approved as a combination therapy as well as a monotherapy to treat patients with two other types of cervical cancers.